

Life Sciences Financing Summary Europe


April 2015

After a strong start of the year in January 2015, with EUR 94m collected by 8 private European Biotech companies (Therapeutics & Diagnostics), there was only one private round raised by a European company in the sector in February, the EUR 9m series A from Swiss Prexton Therapeutics.

The largest European IPO in Life Sciences in the period was also the only one in January, by Danish Ascendis Pharma A/S, at EUR 92.6m, with the most advanced product in Phase II clinical trials, and only one month after completing a USD 60m (EUR 49m) series D financing. In February, three more companies went public: Karessa Pharma Holding AB (EUR 37.9m, preclinical), Bone Therapeutics SA (EUR 32.2m, Phase III) and Poxel SA (EUR 3.6m, Phase II).

The largest private financing round for European Therapeutics & Diagnostics companies in January and February 2015 was raised in February UCL spin-out Autolus, with USD 45m (EUR 39m) investment by Syncona. Continue reading below to learn more about the financing highlights of January and February 2015 in the European Life Science industry.

Europe - Biotech Therapeutic Financing Rounds



Source: BiotechgateBiotechgate.com

*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



Selected financing highlights: companies raising funds

February 2015

Prexton Therapeutics Raises USD 10m (EUR 8.7m) in a Series A Round

Geneva, Switzerland,-Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson's disease, completed a Series A financing USD 10m (EUR 8.7m) on the 24th of February 2015 co-led by Sunstone Capital and Ysios Capital. MS Ventures, the company's founding investor, will also participate.

This first funding will help Prexton Therapeutics to develop novel small molecules that target the metabotropic Glutamate Receptor 4 (mGluR4) up to completion of Phase I. This has the potential to improve motor complications in Parkinson's disease patients. (*Source: press release*).

January 2015

Autolus, launches with USD 45m (EUR 39m) investment

A new University College London (UK) spin-out company – Autolus – was launched on the 22nd of January 2015 to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of USD 45m (EUR 39m) in investment from healthcare investment company Syncona.

The biopharmaceutical company is founded upon the work of Dr Martin Pule, an academic clinical haematologist and thought-leader in T-cell engineering based at UCL, and has been spun-out of UCL by UCL Business, the university's technology transfer company.

Recent clinical trials of engineered T-cell treatments for haematological malignancies performed by various groups suggest that chimeric antigen receptor ("CAR") T-cells have the potential to transform cancer therapy. (*Source: press release*)



Selected financing highlights – investors in January, February 2015

The following investors have made investments into European Life Science companies through January, February 2015:

- Aescap Venture
- BB Biotech Ventures
- BioMedInvest
- Consort Medical plc
- Idinvest Partners
- Johnson & Johnson Innovation - JJDC, Inc.
- Kurma Partners
- LSP
- MS Ventures
- Novartis Venture Funds
- Novo A/S
- RMI Partners
- South West Ventures Fund
- Sunstone Capital
- Syncona Partners
- Ysios Capital
- VI Partners




Quarterly Biotech Equity Financing Breakdown by Size of Investment (Therapeutics & Diagnostics)


The last quarter of 2014 was dominated by private investments smaller than EUR 5m in Biotech companies (Therapeutics and Diagnostics), in a trend only broken in the third quarter of the year, where the majority of investments were between EUR 5m and EUR 15m. Nonetheless, Q4 2014 was the second in the proportion of investments between EUR 5m and EUR 15m that made 32% of the total, compared to 23% in Q2 and 22% in Q1.

Overall, in 2014 just under half of investments (48%) were in the smallest category, with 30% between EUR 5m and EUR 15m, 13% between EUR 15m and EUR 30m, and 9% over EUR 30m

Investment Size as % of Total - Biotech T&D (Europe)



*The graph above shows the proportion of financing rounds by most advanced project phase in the therapeutics and diagnostics category per quarter. All units are in EUR and include only private companies



January, February 2015 financing rounds summary

Source: Biotechgate – www.biotechgate.com

| Company Name | Sector | Amount (in Million EUR) | Ownership | Country |
|-----------------------------|------------------------------|-------------------------|-----------------------|----------------|
| Cardio3 BioSciences | Therapeutics and Diagnostics | 31.7 | Public | Belgium |
| Prexton Therapeutics | Therapeutics and Diagnostics | 8.7 | Private / independent | Switzerland |
| Quantum Genomics | Therapeutics and Diagnostics | 33.2 | Public | France |
| NeuroVive Pharmaceutical AB | Therapeutics and Diagnostics | 3.0 | Public | Sweden |
| Cortendo AB | Therapeutics and Diagnostics | 24.3 | Public | Sweden |
| Karessa Pharma Holding AB | Therapeutics and Diagnostics | 37.9 | Public | Sweden |
| Poxel SA | Therapeutics and Diagnostics | 23.3 | Public | France |
| Poxel SA | Therapeutics and Diagnostics | 3.6 | Public | France |
| ThromboGenics NV | Therapeutics and Diagnostics | 1.1 | Public | Belgium |
| Bone Therapeutics S. A. | Therapeutics and Diagnostics | 32.2 | Public | Belgium |
| ZEDIRA GmbH | Biotechnology / R&D Services | 5.0 | Private / independent | Germany |
| Medyria | Medical Technology | 2.0 | Private / independent | Switzerland |
| Atlas Genetics | Biotechnology / R&D Services | 17.1 | Private / independent | United Kingdom |
| Inoviem scientific | Biotechnology / R&D Services | 0.5 | Private / independent | France |
| Ascendis Pharma A/S | Therapeutics and Diagnostics | 92.6 | Public | Denmark |
| TxCell | Therapeutics and Diagnostics | 1.7 | Public | France |
| ProteoMediX AG | Therapeutics and Diagnostics | 0.9 | Private / independent | Switzerland |
| Genenta Science | Therapeutics and Diagnostics | 6.2 | Private / independent | Italy |
| Galapagos NV | Therapeutics and Diagnostics | 2.5 | Public | Belgium |
| Autolus Limited | Therapeutics and Diagnostics | 39.0 | Private / independent | United Kingdom |

| | | | | |
|--------------------------|------------------------------|------|-----------------------|----------------|
| Ultimovacs AS | Therapeutics and Diagnostics | 5.0 | Private / independent | Norway |
| Gecko Biomedical | Medical Technology | 1.3 | Private / independent | France |
| Sensorion SAS | Therapeutics and Diagnostics | 2.0 | Private / independent | France |
| NovaBiotics Ltd | Therapeutics and Diagnostics | 6.5 | Private / independent | United Kingdom |
| IO Biotech ApS | Therapeutics and Diagnostics | 3.0 | Private / independent | Denmark |
| Cortendo AB | Therapeutics and Diagnostics | 23.5 | Public | Sweden |
| EffRx Pharmaceuticals SA | Pharma | 2.1 | Private / independent | Switzerland |
| UroSens Ltd | Medical Technology | 2.6 | Private / independent | United Kingdom |
| Orphazyme ApS | Therapeutics and Diagnostics | 20.0 | Private / independent | Denmark |
| Genkyotex SA | Therapeutics and Diagnostics | 18.0 | Private / independent | Switzerland |



About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60
Web: www.venturevaluation.com

Copyright © 2015 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebiotech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com

Email: info@venturevaluation.com